Potentials for the management of cardiovascular risk in diabetic patients on insulin therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Diabetes mellitus (DM) contributes to the development of a number of severe vascular complications and a significant increase in cardiovascular risk, which leads to early disability and premature death of patients. The evaluation of cardiovascular safety of both new and traditionally used for many years hypoglycemic drugs and their combinations contributes to the development of more effective therapeutic strategies and recommendations for the prevention of adverse cardiovascular events and improve the prognosis of diabetes. The article presents a comparative analysis of the safety of basal insulin analogues for DM2 patients in relation to the risk of developing severe hypoglycemia and cardiovascular safety. Analysis of data from randomized clinical trials, databases of real-life clinical practice, as well as the largest study of cardiovascular safety of insulin analogues to date, DEVOTE study, makes it clear that insulin degludec, possessing sugar-lowering efficacy and cardiovascular safety comparable to other basal insulin preparations, has several advantages, namely a lower risk of developing severe hypoglycemic episodes, a greater likelihood of achieving target levels of fasting glycemia, as well as the possibility of a more flexible regimen of drug administration.

Full Text

Restricted Access

About the authors

Gagik R. Galstyan

National Medical Research Center for Endocrinology

Email: galstyangagik964@gmail.com
SPIN-code: 9815-7509
MD, Professor

M. B Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

SPIN-code: 1035-4773

Ya. G Alekseeva

SPIN-code: 4954-0700

References

  1. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г Сахарный диабет. 2018;21(3):144-59.
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический отчет по данным Федерального регистра сахарного диабета. Сахарный диабет 2017;20(1):13-
  3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12.
  4. Seshasai S.R., Kaptoge S., Thompson A., et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl J. Med. 2011;364:829-41. Doi: W.W56/NEJMoaW08862.
  5. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371 (9626):1800-809. Doi:10.1016/ S0140-6736(08)60768-0.
  6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet. 1998;352:837-53.
  7. Stratton I.M., Adler A.I., Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405-12.
  8. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl J. Med. 2008;358:2545559.
  9. Riddle M.C., Ambrosius W.T., Brillon D.J., et al. Epidemiologic relationships between A1C and allcause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983-90. Doi: 10.2337/ dc09-1278.
  10. Duckworth W., Abraira C., Moritz T., et al. Glucose Controle and Vascular Complications in Veterans with Type 2 Diabetes. N. Engl J. Med. 2009;360:129-39. Doi: 10.1056/ NEJMoa0808431.
  11. ADVANCE Collaborative Group, Patel A., MacMahon S. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358(24):2560-72. doi: 10.1056/NEJMoa0802987.
  12. Ceriello A., Novials A., Ortega E., et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61:2993-97. doi: 10.2337/db12-0224.
  13. Zinman B., Marso S.P., Poulter N.R., et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:48-57. Doi: 10.1007/ s00125-017-4423-z
  14. Laight D.W., Carrier M.J., Ànggârd E.E. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev. 1999;15:274-82
  15. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-87. doi: 10.1007/s00125-010-1684-1
  16. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care. 2010;33:442-49. doi: 10.2337/dc09-0749.
  17. Laakso M., Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. NatRev Endocrinol. 2014;10(5):293-302. doi: 10.1038/nrendo.2014.29.
  18. Martin-Timon I., Sevillano-Collantes C., Marfn-Penalver J.J., del Canizo-Gomez FJ. Management of cardiovascular risk factors in type 2 diabetes mellitus patients. EMJ. 2016;1(4):89-97.
  19. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008.
  20. European Medicines Agency Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012.
  21. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет. 2017;20(1):1-121.
  22. Rensinga K.L., von der Thüsenb J.H., Weijers E.M., et al. Endothelial insulin receptor expression in human atherosclerotic plaques: Linking micro- and macrovascular disease in diabetes? Atherosclerosis. 2012;222:208-15. Doi: 10.1016/j. atherosclerosis.2012.01.035.
  23. Wang X., Yu C., Zhang B., Wang Y. The injurious effects of hyperinsulinism on blood vessels. Cell Biochem Biophys. 2014;69:213-18. doi: 10.1007/s12013-013-9810-6.
  24. Xun P., Wu Y., He Q., He K. Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a metaanalysis of prospective cohort studies. Am J. Clin Nutr. 2013;98(6):1543-54. Doi: 10.3945/ ajcn.113.065565.
  25. Engel-Nitz N.M., Martin S., Sun P., et al. Cardiovascular events and insulin therapy: A retrospective cohort analysis. Diabetes Research and Clinical Practice. 2008;81(1):97-104. doi: 10.1016/j.diabres.2008.02.011.
  26. Li J., Tong Yu., Zhang Yu., Tang L., et al. Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics. 2016;38(2):372-86.e6. doi: 10.1016/j.clinthera.2015.12.006.
  27. Martin-Timon I., Sevillano-Collantes C., Segura-Galindo A., del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J. Diabetes. 2014;5:444-70. doi: 10.4239/wjd.v5.i4.444.
  28. Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl JMed 2016;375: 311-22.
  29. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl J. Med. 2015;373:2117-28.
  30. Schwartz T.B., Meinert C.L. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect. Biol Med. 2004;47:564-74.
  31. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl J. Med. 2008;359:1577-89. doi: 10.1056/NEJMoa0806470.
  32. Malmberg K., Rydén L., Hamsten A., et al. Effects of insulin treatment on cause- specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. European Heart J. 1996;9:1337-44.
  33. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512-20.
  34. Malmberg K., Ryden L., Wedel H., et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61.
  35. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. 2016;39:709-16. Doi: 10.2337/ dc15-1676.
  36. ORIGIN Trial Investigators. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 2016;39(5):709-16. doi: 10.2337/dc15-1676.
  37. Инструкция по медицинскому применению лекарственного препарата Тресиба (URL: http:// grls.rosminzdrav.ru)
  38. Heise T., Hermanski L., Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-64. doi: 10.1111/j.1463-1326.2012.01627.x.
  39. Heise T., Norskov M., Nosek L., et al. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032-39. doi: 10.1111/dom.12938.
  40. Ratner R.E., Gough S.C., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84. doi: 10.1111/dom.12032
  41. Lane W.S., Bailey T.S., Gerety G., et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33-44. Doi: 10.1001/ jama.2017.7115
  42. Wysham C.H., Bhargava A., Chaykin L.B., et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45-56. Doi: 10.1001/ jama.2017.7117
  43. Siegmund T., Tentolouris N., Knudsen S.T., et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. 2018;20:689-697. doi: 10.1111/dom.13149
  44. Marso S.P., McGuire D.K., Zinman B., et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723-32. doi: 10.1056/NEJMoa1615692
  45. Goto A., Arah O.A., Goto M., et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:4533. Doi: 10.1136/ bmj.f4533.
  46. Pieber T.R., Marso S.P., McGuire D.K., et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61:58-65. doi: 10.1007/s00125-017-4422-0.
  47. Frier B.M., Schernthaner G., Heller S.R. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34(2):132-37.
  48. Chow E., Bernjak A, Williams S., et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63:1738-47. Doi: 10.2337/ db13-0468.
  49. Chow E., Bernjak A, Walkinshaw E., et al. Cardiac autonomic regulation and repolarization during acute experimental hypoglycemia in type 2 diabetes. Diabetes. 2017;66:1322-33. doi: 10.2337/db16-1310.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies